Gapping up
In reaction to strong earnings/guidance:
- WW +13%, EAT +12.3%, MTH +9.5%, SPOT +8.7%, ENVA +8.6%, BXMT +8.4%, HELE +7.8%, DXCM +7.6%, CHE +7.1%, GOOG +7.1%, BCS +6.8%, MASI +6%, SHW +6%, DB +5.8%, MKSI +5.5%, WPP +5.3%, BA +5.2%, JNPR +4.9%, LSCC +4.9%, VLO +4.9%, ACA +4.8%, STRA +4.3%, OSK +4%, CLH +3.9%, AJRD +3.8%, CRSP +3.6%, MKTX +3.3%, MRC +3.1%, LH +2.9%, HUM +2.8%, EPD +2.4%, ANTM +2.2%, GRMN +1.9%, BSX +1.8%, YUMC +1.7%, SIMO +1.4%, AZN +1.4%, CSTM +1.3%, OI +1.2%, CVE +1%
Other news:
- CMRX +37.1% (receives FDA clearance for rolling submission for NDA for brincidofovir)
- BNTX +7.5% (BioNTech and Pfizer complete of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany ) INO +6.9% (presents positive data with INO-4700 for MERS coronavirus)
- SUPN +5.2% (to acquire central nervous system portfolio from US WorldMeds for $530 mln)
- CLB +4.1% (cuts dividend)
- DVAX +3.9% (reports data from clinical trial evaluating HEPLISAV-B)
- MET +2.3% (increases dividend)
- AVDL +2.1% (prices offering of 11,630,000 ADSs at $10.75 per ADS)
- PFE +1.4% (BioNTech and Pfizer complete of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany )
Analyst comments:
- RLGY +9.3% (upgraded to Buy from Neutral at Compass Point)
- TJX +2.6% (upgraded to Overweight from Neutral at Atlantic Equities)
- PH +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)